Table of Content

1. Personalized Cancer Vaccine: Revolutionizing the Immunotherapeutics of the Future

1.1 The Approach Towards Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Clinical Trials Scenario


2. Personalized Cancer Vaccine Mechanism of Action

2.1 Entities Involved in Personalized Cancer Vaccine & Their Respective Contributions
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 General Working of Personalized Cancer Vaccine
2.3 Genetic Polymorphism Leading to Pharmacogenomics
2.4 Cancer Pharmacogenomics Observing Somatic Mutations


3. Biomarkers Importance In Personalized Vaccines

3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers


4. Ongoing Clinical Trials on Personalized Medicines

4.1 NEO-PV-01 Showing Glimmers of Success against Melanoma
4.2 Personalized Vaccine: An Evolving Biological Discovery for Pancreatic Cancer
4.3 Precision Cancer Vaccine against Metastatic Colorectal Cancer
4.4 First-in-Human Trial of Personalized Vaccine for Glioblastoma (Brain Tumor)
4.5 TG4001 in Combination with Avelumab against HPV Cancers


5. Immune Checkpoint Biomarkers Preventing Tumor Growth

5.1 Emerging Biomarkers for CTLA4
5.2 PD-1/PD-L1


6. Personalized Cancer Vaccine: Manufacturing Process & Cost Analysis Study

6.1 Pre - Manufacturing Cost Analysis
6.2 Segmented Cost Analysis of Personalized Cancer Vaccine
6.2.1 Capital Cost
6.2.2 Cost of Raw Materials
6.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
6.2.4 Factory & Administrative Overheads
6.2.5 Filling & Packaging
6.3 Per Patient Cost


7. Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment

7.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine
7.2 Increasing Investments
7.3 Personalized Cancer Vaccine Development using mRNA
7.4 Personalized Cancer Vaccine Market Receiving Collaborations & Ventures Ensure Stable Funding
7.5 DNA Sequencing Technology Development Driving the Personalized Cancer Vaccine Market


8. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type

8.1 Personalized Cancer Vaccine Breakthrough against Melanoma
8.2 Lung Cancer Prevention using Personalized Vaccines
8.3 Personalized Cancer Vaccines towards Eliminating Breast Cancer
8.4 Colorectal Cancer Eradication by Personalized Cancer Vaccines
8.5 Scope of Leukemia Treatment using Personalized Cancer Vaccines
8.6 Prostate Cancer Eradication using Personalized Cancer vaccine: Provenge
8.7 Personalized Cancer Vaccines Targeting Cervical Cancer
8.8 Personalized Cancer Vaccines Application towards Glioblastoma (Brain Tumor)


9. Personalized Cancer Vaccine: Rising with New Avenues & Opportunities

9.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline
9.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World


10. Porter’s Five Force Analysis of the Personalized Cancer Vaccine Market

10.1 Bargaining Power of Suppliers
10.2 Bargaining Power of Buyer
10.3 Threats of Substitute Products
10.4 Threat of New Entrants to the already Existing Market
10.5 Rivalry Among the Existing Competitors


11. Factors Driving the Market of Personalized Cancer Vaccine

11.1 Increased Demand for Personalized Cancer Vaccine Production
11.2 Increase Prevalence of Cancer Cases in the Population Worldwide
11.3 Cancer Heterogenetic Environment
11.4 High Level of Specificity
11.5 Assistance from Government
11.6 Advancements in Genome Sequencing Techniques Delivering better Personalized Cancer Vaccines
11.7 Robust Clinical Pipeline Under Development


12. Challenges Associated with Personalized Cancer Vaccine Market

12.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
12.2 Commercial Challenges Surrounding Personalized Cancer Vaccines


13. Global Personalized Cancer Vaccine Market Future Outlook


14. Personalized Medicine Current Market Region Scenario

14.1 North America
14.2 Latin America
14.3 Europe
14.4 Asia-Pacific
14.4.1 Japan
14.4.2 India
14.4.3 South Korea
14.4.4 Taiwan
14.5 Middle East & Africa


15. Global Personalized Vaccine Trends


16. Competitive Landscape

16.1 Advaxis Inc.
16.2 Avax Technologies
16.3 BioNtech AG
16.4 Celldex
16.5 CureVac AG
16.6 Genetech
16.7 Genocea
16.8 Gristone Oncology
16.9 ISA Pharmaceuticals
16.10 Merck
16.11 Moderna Therapeutics
16.12 Neon Therapeutics
16.13 Personalis



List of Figures


Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 4-1: Ongoing Clinical Trials on Personalized Vaccines
Figure 5-1: High Throughput Immune Assessment for Biomarker Discovery
Figure 6-1: General Overview of Personalized Cancer Vaccine Production
Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-7: Gardasil – Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 6-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
Figure 6-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
Figure 6-11: Gardasil – Manufacturing Cost per single Dose (US$), 2018
Figure 6-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
Figure 6-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
Figure 6-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
Figure 6-15: Gardasil & Gardasil 9 - Cost Analysis (US$), October’ 2019
Figure 7-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
Figure 7-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 8-1: Alteration in CDKN2A Mechanism
Figure 8-2: Global - Melanoma & Non – Melanoma Cancer Incidence (000’), 2018
Figure 8-3: Global - Melanoma Prevalence by Region (%), 2018
Figure 8-4: Global - Lung Cancer Incidence & Deaths (Million), 2018
Figure 8-5: Global – Lung Cancer Prevalence by Region (%), 2018
Figure 8-6: Global - Breast Cancer Incidence & Deaths (Million), 2018
Figure 8-7: Global - Breast Prevalence by Region (%), 2018
Figure 8-8: Global - Colorectal Cancer Incidence & Deaths (Million), 2018
Figure 8-9: Global - Colorectal Cancer Market Size (%), 2018
Figure 8-10: Global - Leukemia Incidence (000’), 2018
Figure 8-11: Global - Leukemia Market Size (%), 2018
Figure 8-12: Global - Prostate Cancer Incidence (000’), 2018
Figure 8-13: Global - Prostate Cancer Prevalence by Region (%), 2018
Figure 8-14: Provenge - Cost Analysis (US$/Month)
Figure 8-15: Global - Cervical Cancer Incidence (000’), 2018
Figure 8-16: Global - Cervical Cancer prevalence by Region (%), 2018
Figure 9-1: Global - Oncology Market Size by Region (%), 2017
Figure 10-1: Porter’s Five Force Analysis - Overview
Figure 11-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 11-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 11-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 11-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 12-1: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 13-1: Global - Gardasil/ Gardasil 9 Sales (US$ Billion), 2018 -2026
Figure 13-2: Gardasil/ Gardasil 9 Sales - US v/s Rest of World (US$ Billion), 2018
Figure 13-3: Gardasil/ Gardasil 9 - Global Patent Insight
Figure 13-4: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2019 – 2026
Figure 14-1: US – Total Cancer Deaths, 2016 - 2018
Figure 14-2: Europe – Total Cancer Deaths, 2016 - 2018
Figure 14-3: Asia-Pacific – Total Cancer Deaths, 2018
Figure 14-4: Japan – Total Cancer Deaths, 2016 & 2018
Figure 14-5: India – Total Cancer Deaths, 2014 & 2018
Figure 14-6: South Korea – Total Cancer Deaths, 2014 - 2016
Figure 14-7: Taiwan - Total Cancer Deaths, 2017 – 2018

 

List of Tables


Table 8-1:Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 8-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia